-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 JEHEDUaDspAVZCGqXO0fxR6k9gwzGdNoWEGjL9/x6dxy76M0vhQtgxusMAD3rzd2
 /+uByu482vHp+tXM3+KrYQ==

<SEC-DOCUMENT>0001102624-09-000228.txt : 20090505
<SEC-HEADER>0001102624-09-000228.hdr.sgml : 20090505
<ACCEPTANCE-DATETIME>20090505123401
ACCESSION NUMBER:		0001102624-09-000228
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090505
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090505
DATE AS OF CHANGE:		20090505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		09796351

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucell8k.htm
<DESCRIPTION>IMMUCELL CORPORATION 8-K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: May       05, 2009</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align=center colspan=2 width="40%" valign="top">
<b>ME</b><br>
(State or other jurisdiction <br>of incorporation)
</td>
<td align=center width="20%" valign="top">
<b>001-12934</b><br>
(Commission File Number)
</td>
<td align=center colspan=2 width="40%" valign="top">
<b>01-0382980</b><br>
(IRS Employer <br>Identification Number)
</td>
</tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align="center" colspan=2>
<b>56 Evergreen Drive</b><br>
(Address of principal executive offices)
</td>
<td>&nbsp;</td>
<td align="center" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
</tr>
<tr><td colspan=5 align=center><br>
<b>207-878-2770</b><br>(Registrant's telephone number, including area code)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5 align=center>
<b>Not Applicable</b><br>(Former Name or Former Address, if changed since last report)<br>
</td></tr>
</table>
</center>
<br><br>
</b>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
<dl>
 <dd><font face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
 <dd><font face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  <br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  <br>
</dl>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 2.02. Results of Operations and Financial Condition</b></b><br>
<br>
On May 5, 2009 ImmuCell Corporation (the "Company") issued a press release announcing financial results for the three-month period ended March 31, 2009.  The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
<br>
<br>The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<br>
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br />
<br>

<p>
<b>(a) Financial statements:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(b) Pro forma financial information:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(c) Shell company transactions:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(d) Exhibits</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated May       05, 2009</a></b>
<br>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<br>
<table border="0" width="100%">
<tr>
<td width="50%" valign=top>
Dated: May       05, 2009<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President and CEO</i><br>
</td></tr>
</table>
<hr>
<center>
<table border=0 width="100%">
<tr><td colspan=2>
<center><b>Exhibit Index</b></center>
</td>
</tr>
<tr>
<td width=50% align=center><b><u>Exhibit No.</u></b></td>
<td width=50% align=center><b><u>Description</u></b></td>
</tr>
<tr>
<td align=center>99.1</td>
<td align=center>Press Release of ImmuCell Corporation dated May       05, 2009</td>
</tr>
</table>
</center>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL CORPORATION PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces Financial Results for First Quarter of 2009</b>
<p>PORTLAND, ME -- (Marketwire - May       05, 2009) -  ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the three-month period ended
March 31, 2009.
</p>
<p>
For the three-month period ended March 31, 2009, product sales decreased by
10%, or $171,000, to $1,460,000 in comparison to the same period in 2008.
</p>
<p>
"In the current global economic crisis, dairy producers have been hit with
significant declines in milk revenue," commented Michael F. Brigham,
President and CEO.  "We appreciate the volume of business that we have
maintained during these times when our customers are being forced to cut
costs wherever possible to stay in business."
</p>
<p>
Product development expenses increased by 30%, or $100,000, during the
three-month period ended March 31, 2009 in comparison to the same period in
2008 principally reflecting the costs of funding the development of Mast
Out&#174;.  As of the end of April 2009, approximately 85% of the qualified
cases required to reach the targeted study size had been enrolled in the
pivotal effectiveness study.
</p>
<p>
The Company reported a loss before income taxes of $(36,000) during the
three-month period ended March 31, 2009 in contrast to income before income
taxes of $129,000 during the same period in 2008.  The net loss was
$(35,000) ($(0.01) per diluted share) during the three-month period ended
March 31, 2009 in contrast to net income of $78,000 ($0.03 per diluted
share) during the same period in 2008.
</p>
<p>
Cash, cash equivalents and short-term investments increased by 2%, or
$86,000, to $5,140,000 at March 31, 2009 as compared to $5,054,000 at
December 31, 2008.  Stockholders' equity increased by 1%, or $98,000, to
$9,742,000 at March 31, 2009 as compared to $9,644,000 at December 31,
2008.  The Company had 2,971,000 shares of common stock outstanding as of
March 31, 2009.
</p>
<p>
<pre>
                                                         (Unaudited)
                                                     Three Months Ended
                                                          March 31,
                                                   -----------------------
(In thousands, except per share amounts)              2009         2008
                                                   ----------   -----------
Revenues:
Product Sales                                      $    1,460   $     1,631
Other Revenues                                              1             5
                                                   ----------   -----------
Total Revenues                                          1,461         1,636

Cost and expenses:
Product costs                                             740           814
Product development expenses                              432           332
Selling, general and administrative expenses              361           421
                                                   ----------   -----------
Total costs and expenses                                1,533         1,567
                                                   ----------   -----------

Net operating (loss) income                               (72)           69

Interest and other income                                  36            60
                                                   ----------   -----------

(Loss) income before income taxes                         (36)          129
Income tax (credit) expense                                (1)           51
                                                   ----------   -----------
Net (loss) income                                  $      (35)  $        78
                                                   ==========   ===========

Net (loss) income per common share:
Basic                                              $    (0.01)  $      0.03
Diluted                                            $    (0.01)  $      0.03

Weighted average common shares outstanding:
Basic                                                   2,923         2,892
Diluted                                                 2,923         2,965




                                                   (Unaudited)
                                                       At           At
(In thousands)                                      March 31,  December 31,
                                                       2009        2008
                                                   -----------  -----------
Cash, cash equivalents and short-term investments  $     5,140  $     5,054
Total assets                                            10,233       10,128
Net working capital                                      6,398        6,245
Stockholders&#146; equity                               $     9,742  $     9,644

</pre>
</p>
<p>
<br>
ImmuCell Corporation is a biotechnology company that is developing,
manufacturing and selling products that improve animal health and
productivity in the dairy and beef industries.  Press releases and other
information about the Company are available at http://www.immucell.com.

</p>
<pre>
Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
